From: Neutrophil count is associated with survival in localized prostate cancer
 | Univariate | Multivariate | ||
---|---|---|---|---|
 | HR (95 % CI) | p-value | HR (95 % CI) | p-value |
Age (n = 1772) | 1.06 (1.03 1.10) | 0.001 | 1.05 (1.01–1.10) | 0.008 |
CAPRA (n = 1772) | 1.21 (1.09–1.34) | 0.0002 | 1.16 (1.03–1.30) | 0.015 |
BMI (n = 544) | 1.00 (0.93–1.06) | 0.9 |  |  |
CVD (n = 1772) | 1.79 (1.16–2.77) | 0.009 |  |  |
HTN (n = 1772) | 1.14 (0.74–1.76) | 0.5 |  |  |
Diabetes (n = 1772) | 1.59 (0.94–2.68) | 0.08 |  |  |
Statin use (n = 1772) | 0.82 (0.52–1.28) | 0.4 | 0.70 (0.42–1.14) | 0.15 |
Neutrophils (n = 950) | 1.16 (1.01–1.34) | 0.04 | 1.18 (1.017–1.37) | 0.03 |
Lymphocytes (n = 950) | 1.01 (0.72–1.43) | 0.9 |  |  |
NLR (n = 950) | 1.10 (0.95–1.27) | 0.2 |  |  |
WBC (n = 950) | 1.13 (0.99–1.28) | 0.06 |